AGGRENOX prevents twice as many strokes as aspirin

Aspirin is the most widely used antiplatelet drug because of its effectiveness and low cost. Aspirin work even better in combination with other antiplatelet drugs.

The proven effectiveness of AGGRENOX

The combination of low-dose aspirin and extended-release dipyridamole in AGGRENOX was studied in the largest stroke prevention trial ever: The Second European Stroke Prevention Study (ESPS 2).

A total of 6,602 ischemic stroke or TIA patients in 13 Western European countries were studied over 2 years.

The study found:

AGGRENOX prevented twice as many strokes as aspirin
AGGRENOX was highly effective at preventing stroke in patients with common vascular diseases including high blood pressure and heart disease
AGGRENOX prevented more than twice as many fatal and nonfatal ischemic events (stroke, heart attack) as aspirin alone

As a result, AGGRENOX is recommended as a first-line treatment option for reducing the risk of stroke after TIA/stroke by:

National Stroke Association
American Heart Association
American College of Chest Physicians

WHAT’S RELATED?

You may also be interested in reading:

How AGGRENOX works
AGGRENOX Safety

Get FREE resources on TIA and AGGRENOX. Click here

If you can’t afford your AGGRENOX, our patient assistance program may be able to help.
Call 1 800 556 8317.

Important Information about AGGRENOX

AGGRENOX is indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis.

The most common adverse event with AGGRENOX was headache (39.2% vs 32.9% with placebo), which was more frequent at the onset of therapy but diminished over time. In ESPS 2, GI bleeding with AGGRENOX was comparable to aspirin (4.1% vs 3.2%) and the incidence of intracranial hemorrhage was nine (9) patients (0.6%) in the AGGRENOX group, six (6) patients (0.5%) in the extended-release dipyridamole group, six (6) patients (0.4%) in the aspirin group and seven (7) patients (0.4%) in the placebo group.

AGGRENOX contains aspirin. Patients who consume three or more alcoholic drinks every day should be counseled about the bleeding risks involved with chronic, heavy alcohol use while taking aspirin. Even low doses of aspirin can increase bleeding time, which can adversely affect patients with bleeding disorders. Patients with a history of active peptic ulcer disease should avoid using aspirin, which can cause gastric mucosal irritation and bleeding. AGGRENOX should be avoided in the third trimester of pregnancy.

Click here for full AGGRENOX Prescribing Information.